

DAFTAR PUSTAKA

1. Blum W. Acute myeloid leukemia. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL, editors. *Harrison's Principles of Internal Medicine*. 21st ed. New York: McGraw-Hill Education; 2022.
2. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic/dendritic neoplasms. *Leukemia*. 2022;36:1703–19.
3. Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. *Am J Hematol*. 2023;98:502–26.
4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71:209–49.
5. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2024;74:229–63.
6. National Cancer Institute. SEER Cancer Stat Facts: Leukemia—Acute Myeloid Leukemia (AML) [Internet]. Surveillance, Epidemiology, and End Results Program; 2024 [cited 2024 Nov 3]. Available from: <https://seer.cancer.gov/statfacts/html/amyl.html>
7. Cancer Research UK. Acute myeloid leukaemia (AML) statistics [Internet]. 2020 [cited 2024 Nov 3]. Available from: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-aml>
8. Irawan C, Steven R, Gunarsa RG, Tenggara JB. Luaran hasil leukemia mieloid akut yang menjalani terapi pada ruang kemoterapi semi-isolasi. *J Penyakit Dalam Indones*. 2022;9:155.

9. Cahya Wibawa IMB, Subawa AAN, Sutirta Yasa IWP, Mahartini NN. Gambaran karakteristik pasien acute myeloid leukemia di RSUP Sanglah Denpasar tahun 2018. *E-Jurnal Medika Udayana*. 2021;10:38.
10. Rahmadin B, Wahid I, Yaswir R. Profil penderita leukemia mieloblastik akut di Bagian Penyakit Dalam RSUP Dr. M. Djamil Padang. *J Kesehatan Andalas*. 2018;6:495.
11. Salsabila Z, Afriant R, Rofinda ZD, Elvira D, Yaswir R, Izzah AZ. Hubungan anemia dengan remisi komplik kemoterapi induksi pada pasien leukemia mieloblastik akut dewasa di RSUP Dr. M. Djamil Padang. *J Ilmu Kesehatan Indones*. 2024;5:26–32.
12. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood*. 2022;140:1345–77.
13. Short N, Rytting M, Cortes J. Acute myeloid leukaemia. *Lancet*. 2018;392:593–606.
14. Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, et al. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. *Cancer*. 2023;129:1856–65.
15. Liu CJ, Hong YC, Kuan AS, Yeh CM, Tsai CK, Liu YC, et al. The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia. *Cancer Med*. 2020;9:1572–80.
16. Bhatt VR, Shostrom V, Giri S, Gundabolu K, Monirul Islam KM, Appelbaum FR, et al. Early mortality and overall survival of acute myeloid leukemia based on facility type. *Am J Hematol*. 2017;92:764–71.
17. Lai C, Bhansali RS, Kuo EJ, Mannis G, Lin RJ. Older adults with newly diagnosed AML: Hot topics for the practicing clinician. *Am Soc Clin Oncol Educ Book*. 2023;;1–16.
18. Abuelgasim KA, Albuhayri B, Munshi R, Al Mugairi A, Alahmari B, Gmati G, et al. Impact of age and induction therapy on outcome of 180 adult

patients with acute myeloid leukemia: Retrospective analysis and literature review. *Leuk Res Rep.* 2020;14.

19. Li YC, Shih YH, Chen TC, Gau JP, Su YC, Chen MH, et al. Redefining remission induction chemotherapy ineligibility by early mortality in de novo acute myeloid leukemia. *J Clin Med.* 2021;10:1–9.
20. Morishima T, Sato A, Nakata K, Matsumoto Y, Koeda N, Shimada H, et al. Barthel Index-based functional status as a prognostic factor in young and middle-aged adults with newly diagnosed gastric, colorectal and lung cancer: A multicentre retrospective cohort study. *BMJ Open.* 2021;11:1–10.
21. Ho G, Jonas BA, Li Q, Brunson A, Wun T, Keegan THM. Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. *Br J Haematol.* 2017;177:791–9.
22. Yilmaz S, Çeneli Ö. Prognostic value of neutrophil-to-lymphocyte ratio in acute myeloid leukemia. *Open J Intern Med.* 2023;13:131–8.
23. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, et al. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. *Am J Hematol.* 2022;97:68–78.
24. Kantarjian H, Welch MA, Sasaki K. Early mortality after chemotherapy as a quality indicator—the leukemia perspective. *Blood Cancer J.* 2023;13:–.
25. Nix M, Price A. Acute myeloid leukemia: An ever-changing disease. *J Adv Pract Oncol.* 2019;10:4–8.
26. Stubbins RJ, Francis A, Kuchenbauer F, Sanford D. Management of acute myeloid leukemia: A review for general practitioners in oncology. *Curr Oncol.* 2022;29:6245–59.
27. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. *Blood Rev.* 2019;36:70–87.
28. Jani CT, Ahmed A, Singh H, Mouchati C, Al Omari O, Bhatt PS, et al. Burden of AML, 1990–2019: Estimates from the Global Burden of Disease Study. *JCO Glob Oncol.* 2023;1–11.
29. Döhner H, Weisdorf DJ, Bloomfield C. Acute myeloid leukemia. *N Engl J Med.* 2015;373:1136–52.

30. Soebandrio A, Soedarsono S, Alwi I, Simadibrata M, Setiati S, Syam AF, et al. *Buku Ajar Ilmu Penyakit Dalam*. 7th ed. Jakarta: Interna Publishing; 2024.
31. Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: Can a better understanding of the underlying molecular pathophysiology lead to novel treatments? *Cells*. 2020;9.
32. Rangel FAL, Valencia VC, Guijosa MÁG, Penagos CC. Acute myeloid leukemia—genetic alterations and their clinical prognosis. *Int J Hematol Oncol Stem Cell Res*. 2017;11:328–39.
33. Saultz JN, Garzon R. Acute myeloid leukemia: A concise review. *J Clin Med*. 2016;5:1–17.
34. Ferrara F, Vitagliano O. Induction therapy in acute myeloid leukemia: Is it time to put aside standard 3+7? *Hematol Oncol*. 2019;37:558–63.
35. RSUP Dr. M. Djamil Padang. *Panduan Praktik Klinik Leukemia Akut*. Padang: RSUP Dr. M. Djamil Padang; 2024.
36. Klepin HD. Geriatric perspective: How to assess fitness for chemotherapy in acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program*. 2014;2014:8–13.
37. Weigert N, Rowe JM, Lazarus HM, Salman MY. Consolidation in AML: Abundant opinion and much unknown. *Blood Rev*. 2022;51:100873.
38. Talati C, Dhulipala VC, Extermann M, Al Ali N, Kim J, Komrokji R, et al. Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia. *Haematologica*. 2020;105:398–406.
39. Naoe T. How to improve outcomes of elderly patients with acute myeloid leukemia: Era of excitement. *Nagoya J Med Sci*. 2020;82:151–60.
40. Choi JH, Shukla M, Abdul-Hay M. Acute myeloid leukemia treatment in the elderly: A comprehensive review of the present and future. *Acta Haematol*. 2023;146:431–57.
41. Hernández-Quiles C, Bernabeu-Wittel M, Pérez-Belmonte LM, Macías-Mir P, Camacho-González D, Massa B, et al. Concordance of Barthel Index, ECOG-PS, and Palliative Performance Scale in the assessment of functional

status in patients with advanced medical diseases. *BMJ Support Palliat Care*. 2017;7:300–7.

42. Dhakal P, Shostrom V, Al-Kadhimi ZS, Maness LJ, Gundabolu K, Bhatt VR. Usefulness of Charlson Comorbidity Index to predict early mortality and overall survival in older patients with acute myeloid leukemia. *Clin Lymphoma Myeloma Leuk*. 2020;20:804–12.
43. Li S, Chen L, Jin W, Ma X, Ma Y, Dong F, et al. Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: a meta-analysis. *Sci Rep*. 2017;7.
44. Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, et al. Acute myeloid leukaemia in adult patients; ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. *Ann Oncol*. 2020;31:697–712.
45. Oberoi S, Lehrnbecher T, Phillips R, Hitzler JK, Ethier MC, Beyene J, et al. Early mortality in hyperleukocytosis in patients with acute myeloid leukemia: a systematic review and meta-analysis. *Blood*. 2013;122:2647–57.
46. Bumbea H, Vladareanu AM, Dumitru I, Popov VM, Ciufu C, Nicolescu A, et al. Platelet defects in acute myeloid leukemia: potential for hemorrhagic events. *J Clin Med*. 2021;11:1–10.
47. Secreto C, Chean D, van de Louw A, Kouatchet A, Bauer P, Cerrano M, et al. Characteristics and outcomes of patients with acute myeloid leukemia admitted to intensive care unit with acute respiratory failure: a post-hoc analysis of a prospective multicenter study. *Ann Intensive Care*. 2023;13:79.
48. Woike P. Study of liver and kidney biochemical variations in patients with various morphological types of leukemia at a tertiary healthcare hospital. *J Med Sci Clin Res*. 2018;6:1–6.
49. Spinelli I, De Santis A, Cesini L, Riminucci M, Corsi A, Forlino M, et al. Acute hepatitis-like presentation with cholestasis of CBFB–MYH11-positive acute myeloid leukemia in an adult male: a case report. *J Med Case Rep*. 2022;16:294.

50. Stefaniuk P, Szymczyk A, Podhorecka M. The neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as new prognostic factors in hematological malignancies: a narrative review. *Cancer Manag Res.* 2020;12:2961–77.
51. Papadantonakis N, Erba HP. Recently approved molecularly targeted therapies in AML. *Adv Cell Gene Ther.* 2019;3:1–8.
52. Amini M, Sharma R, Jani C. Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020. *Arch Public Health.* 2023;81:151.
53. Wan X, Tao T, Zhang J, Li N, Gou Y, Yang W, et al. Effect of age, sex and season on acute myeloid leukemia clinical characteristics: a retrospective study. *J Inflamm Res.* 2025;18:2363–75.
54. Linet MS, Curtis RE, Schonfeld SJ, Vo JB, Morton LM, Dores GM. Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001–2019. *eClinicalMedicine.* 2024;71.
55. Ozga M, Nicolet D, Mrózek K, Yilmaz AS, Kohlschmidt J, Larkin KT, et al. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). *Leukemia.* 2024;38:45–57.
56. Weiss JJ, Yates SJ, Badar T, Patel AA, Winer ES, Litzow MR, et al. Association between body mass index and outcomes in patients with newly diagnosed acute myeloid leukemia treated with hypomethylating agents and venetoclax. *Blood.* 2024;144:1489–95.
57. Kementerian Kesehatan Republik Indonesia. Survei Kesehatan Indonesia (SKI): laporan tematik SKI 2023. Jakarta: Badan Kebijakan Kesehatan; 2023.
58. Wedding U, Röhrig B, Klippstein A, Fricke HJ, Sayer HG, Höffken K. Impairment in functional status and survival in patients with acute myeloid leukaemia. *J Cancer Res Clin Oncol.* 2006;132:665–71.
59. Jain H, Eipe T, Shetty A, Nayak L, Bagal BP, Sharma N, et al. Real-world analysis evaluating treatment eligibility and outcomes in patients with AML

receiving intensive chemotherapy: insights from an underrepresented population. *JCO Glob Oncol*. 2025;11.

60. Muhandiramge J, Orchard SG, Warner ET, van Londen GJ, Zalcberg JR. Functional decline in the cancer patient: a review. *Cancers*. 2022;14:1–12.
61. Dhakal P, Shostrom V, Al-Kadhim ZS, Maness LJ, Gundabolu K, Bhatt VR. Usefulness of Charlson Comorbidity Index to predict early mortality and overall survival in older patients with acute myeloid leukemia. *Clin Lymphoma Myeloma Leuk*. 2020;20:804–12.
62. Dhopeshwarkar N, Iqbal S, Wang X, Salas M. A retrospective study of comorbidities and complications in elderly acute myeloid leukemia patients in the United States. *Clin Lymphoma Myeloma Leuk*. 2019;19:436–56.
63. Pulko N, Petreski T, Hauptman Faletic J, Piko N, Roškar Z, Bevc S. The impact of kidney function on survival in elderly patients diagnosed with acute myeloid leukemia. *Clin Nephrol*. 2021;96:1–6.
64. Harystha M. Gambaran karakteristik pasien leukemia mieloid akut di Bagian Penyakit Dalam RSUP Dr. M. Djamil Padang periode Juli 2015–Juni 2016. 2016.
65. Kosasih AS, Setiawan L, Hartini SRI, Kresno SB. Immunophenotyping in the diagnosis and classification of acute leukemia: —Dharmais Cancer Hospital experience. *Indones J Cancer*. 2011;5:3–8.
66. Surapally S, Tenen DG, Pulikkan JA. Emerging therapies for inv(16) AML. *Blood*. 2021;137:2579–84.
67. Falini B, Dillon R. Criteria for diagnosis and molecular monitoring of NPM1-mutated AML. *Blood Cancer Discov*. 2024;5:8–20.
68. Guarnera L, D’Addona M, Bravo-Perez C, Visconte V. KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives. *Int J Mol Sci*. 2024;25:1–14.
69. Çınar O, Malkan UY, Aladağ E, Demiroglu H, Büyükaşık Y, Goker H, et al. Anemia in patients with acute myeloid leukemia revisited: prognostic importance of anemia on treatment-naïve patients. *Acta Medica*. 2025;56:116–21.

70. De Jonge HJM, Valk PJM, de Bont ESJM, Schuringa JJ, Ossenkoppele G, Vellenga E, et al. Prognostic impact of white blood cell count in intermediate-risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. *Haematologica*. 2011;96:1310–7.
71. Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. *Blood*. 2015;125:3246–52.
72. Krüger K, Gabdoulline R, Wichmann M, Schmidt BMW, Götze K, Braitsch K, et al. Prognostic role of kidney disease in newly diagnosed acute myeloid leukemia under venetoclax-based low-intensity therapy. *Cancers*. 2025;17:1–12.
73. Ballo O, Eladly F, Büttner S, Stratmann JA, Rudolf S, Brunnberg U, et al. Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy. *Ann Hematol*. 2021;100:1159–67.
74. Lee SW, Kim MS, Kim YJ, Jung HY, Choi JY, Cho JH, et al. Severe acute kidney injury associated with transformation of chronic myelomonocytic leukemia into acute myeloid leukemia: a case report. *J Clin Med*. 2024;13:1–5.
75. Islam T, Rahman AKMS, Hasan MK, Jahan F, Mondal MC, Ferdoushi S, et al. Liver function tests in patients of acute leukemia before and after induction chemotherapy. *J Biosci Med*. 2020;8:110–21.
76. Jumaah HM, Yenzeel JH, Mehdi MG. Evaluation of some biochemical parameters and hormones in patients with acute myeloid leukemia in Iraq. *Iraqi J Sci*. 2021;62:1460–6.
77. Zhang Q, Yang Q, Weng Y, Huang Z, Chen R, Zhu Y, et al. Neutrophil-to-lymphocyte ratio correlates with prognosis and response to chemotherapy in patients with non-M3 de novo acute myeloid leukemia. *Transl Cancer Res*. 2021;10:1013–24.
78. Hasserjian RP, Campigotto F, Klepeis V, Fu B, Wang SA, Bueso-Ramos C, et al. De novo acute myeloid leukemia with 20–29% blasts is less aggressive than acute myeloid leukemia with $\geq 30\%$ blasts in older adults: a Bone Marrow Pathology Group study. *Am J Hematol*. 2014;89:193–9.

79. Marshalek JP, Epistola R, Tomassetti S. Real-world treatment outcomes from a retrospective cohort of patients with acute myeloid leukemia from an urban safety net hospital. *J Oncol Pharm Pract*. 2025;31:182–9.
80. Mohamed S, Shawayli H, Abbas F, Soliman DS, Afana M, Yassin MA, et al. Hyperleukocytosis in patients with acute myeloid leukemia: characteristics and outcome, a single-center experience. *Blood*. 2023;142:5836–45.
81. Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. *Leukemia*. 2020;34:3149–60.
82. Tober R, Schnetzke U, Fleischmann M, Yomade O, Schrenk K, Hammersen J, et al. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. *J Cancer Res Clin Oncol*. 2023;149:1569–83.
83. Pagano L, Caira M, Nosari A, Rossi G, Viale P, Aversa F, et al. Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e-Chart Registry. *Arch Intern Med*. 2011;171:1502–3.
84. Huoi C, Vanhems P, Nicolle MC, Michallet M, Bénet T. Incidence of hospital-acquired pneumonia, bacteraemia and urinary tract infections in patients with haematological malignancies, 2004–2010: a surveillance-based study. *PLoS One*. 2013;8.
85. Deinhardt-Emmer S, Chousterman BG, Schefold JC, Flohé SB, Skirecki T, Kox M, et al. Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies. *Lancet Respir Med* [Internet]. 2025;13:623–37.
86. Malik IA, Cardenas-Turanzas M, Gaeta S, Borthakur G, Price K, Cortes J, et al. Sepsis and acute myeloid leukemia: a population-level study of comparative outcomes of patients discharged from Texas hospitals. *Clin Lymphoma Myeloma Leuk*. 2017;17:27–32.
87. Mendes FR, da Silva WF, da Costa Bandeira de Melo R, Silveira DRA, Velloso EDRP, Rocha V, et al. Predictive factors associated with induction-

- related death in acute myeloid leukemia in a resource-constrained setting. *Ann Hematol.* 2022;101:147–54
88. Meillon-Garcia LA, Demichelis-Gómez R. Access to therapy for acute myeloid leukemia in the developing world: Barriers and solutions. *Current Oncology Reports.* 2020;22:125.
89. Lopez-Garcia YK, Valdez-Carrizales M, Nuñez-Zuno JA, Apodaca-Chávez E, Rangel-Patiño J, Demichelis-Gómez R. Are delays in diagnosis and treatment of acute leukemia in a middle-income country associated with poor outcomes? A retrospective cohort study. *Hematology, Transfusion and Cell Therapy.* 2024;46:366–73.
90. Zawam H, Salama R, Alsirafy S, Bishr M. Treatment outcome of acute myeloid leukemia in Egypt: A developing country perspective. 2019;1:53–9.
91. Stabellini N, Tomlinson B, Cullen J, Shanahan J, Waite K, Montero AJ, et al. Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survival. *Cancer Medicine.* 2023;12:6711–21.
92. Ansarian MA, Fatahichegeni M, Ren J, Wang X. Sex and gender in myeloid and lymphoblastic leukemias and multiple myeloma: From molecular mechanisms to clinical outcomes. *Current Oncology (Toronto, Ont).* 2025;32.
93. Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. *Haematologica.* 2012;97:1401–4.
94. Enßle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, et al. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: A real-world registry experience. *British Journal of Cancer.* 2023;129:1126–33.
95. Foran JM, Sun Z, Lai C, Fernandez HF, Cripe LD, Ketterling RP, et al. Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis. *Cancer.* 2023;129:2479–90.

96. Tawfik B, Pardee TS, Isom S, Sliesoraitis S, Winter A, Lawrence J, et al. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). *Journal of Geriatric Oncology*. 2016;7:24–31.
97. Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, et al. Significance of FAB subclassification of —acute myeloid leukemia, NOS in the 2008 WHO classification: Analysis of 5848 newly diagnosed patients. *Blood*. 2013;121:2424–31.
98. Padilha SL, Souza EJS, Matos MCC, Domino NR. Acute myeloid leukemia: Survival analysis of patients at a university hospital of Paraná. *Revista Brasileira de Hematologia e Hemoterapia*. 2015;37:21–7.
99. Stefaniuk P, Muzyka-Kasietczuk J, Koczkodaj D, Hus M, Podhorecka M. Reading between the lines: Complete blood count-derived parameters as prognostic factors in patients with newly diagnosed acute myeloid leukemia. *Clinical Medicine Insights: Oncology*. 2025;19.
100. Juga M, Virijević M. Prognostic risk factors for early death in patients with acute myeloid leukemia. *Serbian Journal of the Medical Chamber*. 2022;3:16–25.
101. Fontes HMF, de Freitas JP, Oliveira JHV, de Sousa Moraes ÉA, Rego EM, Melo RAM. Causes and risk factors for early death in adult patients with acute promyelocytic leukemia: A real-life experience. *Hematology, Transfusion and Cell Therapy*. 2024;46:S122–8.
102. Rinaldi I, Sutandyo N, Winston K. Comparison of early mortality between leukapheresis and non-leukapheresis in adult acute myeloid leukemia patients with hyperleukocytosis: A systematic review and meta-analysis. *Hematology (United Kingdom)*. 2022;27:141–9.
103. Gong J, Wu B, Guo T, Zhou S, He B, Peng X. Hyperleukocytosis: A report of five cases and review of the literature. *Oncology Letters*. 2014;8:1825–7.
104. Finkel KW. Chapter 10 – Renal effects of leukemia and lymphoma. In: Finkel KW, Howard SC, editors. Academic Press; 2014.161–5.
105. Mathews E, Laurie T, O’Riordan K, Nabhan C. Liver involvement with acute myeloid leukemia. *Case Reports in Gastroenterology*. 2008;2:121–4.

106. Fu SH, Flannery AH, Thompson Bastin ML. Acute hepatotoxicity after high-dose cytarabine for the treatment of relapsed acute myeloid leukemia: A case report. *Hospital Pharmacy*. 2019;54:160–4.
107. Reville PK, Nogueras González GM, Ravandi F, Sasaki K, Borthakur G, Garcia-Manero G, et al. Predictors of early mortality, response, and survival in newly diagnosed acute myeloid leukemia (AML) using a contemporary academic cohort. *Blood*. 2020;136:44–5.
108. Buckley SA, Othus M, Vainstein V, Abkowitz JL, Estey EH, Walter RB. Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. *American Journal of Hematology*. 2014;89:423–8.
109. Jaime-Pérez JC, Ramos-Dávila EM, Picón-Galindo E, Jiménez-Castillo RA, León AG de, Gómez-Almaguer D. Outcomes and survival predictors of Latin American older adults with acute myeloid leukemia: Data from a single center. *Hematology, Transfusion and Cell Therapy*. 2023;45:S43–50.
110. Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. *Blood*. 2009;113:28–36.
111. Singh S, Lionel S, Jain H, Rajendra A, Nayak L, Selvarajan S, et al. Treatment challenges and outcomes of older patients with acute myeloid leukemia from India. *Annals of Hematology*. 2024;103:4079–88.
112. Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, et al. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. *Blood*. 2009;113:4179–87.
113. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129:424–47.
114. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. *Blood*. 2006;107:3481–5.

115. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. *Blood*. 2015;125:1367–76.
116. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. *Blood*. 2013;121:4287–94.
117. Gopishetty S, Jaiyesimi IA, Ezekwudo D. Outcomes of acute myeloid leukemia patients aged 60 years and above: An analysis of SEER data. *Blood*. 2024;144:7924–7924.
118. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment. *Journal of Clinical Oncology*. 2011;29:4417–23.
119. Paras G, Othus M, Schonhoff K, Shaw C, Sorrow M, Halpern AB, et al. Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms. *Leukemia*. 2023;37:231–4.
120. Hao Q, Foroutan F, Han MA, Devji T, Nampo FK, Mukherjee S, et al. Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review. *PLoS One*. 2022;17.
121. Nipp RD, Rao AV. Performance status in elderly patients with acute myeloid leukemia: Exploring gene expression signatures of cytokines and chemokines. *Journals of Gerontology Series A: Biological Sciences and Medical Sciences*. 2015;70:714–21.
122. Zhang Y, Gu H, Chen Q, Zhang Y, Cheng H, Yang J, et al. Low platelet counts at diagnosis predict better survival for patients with intermediate-risk acute myeloid leukemia. *Acta Haematologica*. 2020;143:9–18.
123. Ling C, Cao NN, Niu XW, Xu SY, Gong WY, Bao WQ, et al. Prognostic impact of initial platelet count and post-induction platelet recovery in elderly AML patients: Associated with circulating cytokines. *Frontiers in Oncology*. 2025;15.

124. Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given —intense induction regimens: A report from SWOG and MD Anderson. *Leukemia*. 2014;28:289–92.
125. Kirby E, Markert R, Marinella M. Prognostic value of initial blood cell counts in acute myeloid leukemia. *Blood*. 2020;136:1.
126. Estey EH. Acute myeloid leukemia: 2021 update on risk-stratification and management. *American Journal of Hematology*. 2020;95:1368–98.
127. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127:2391–405.
128. Mulas O, Mola B, Madeddu C, Caocci G, Macciò A, Nasa GL. Prognostic role of cell blood count in chronic myeloid neoplasm and acute myeloid leukemia and its possible implications in hematopoietic stem cell transplantation. *Diagnostics*. 2022;12.
129. Mushtaq MU, Chaudhary SG, Guru Murthy GS, Hall AC, Atallah EL, Mattison RJ. Prognostic significance of neutrophil-to-lymphocyte ratio in relapsed/refractory acute myeloid leukemia. *Blood*. 2018;132:5246.
130. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. *Nature Reviews Immunology*. 2011;11:519–31.
131. Mendes FR, Silva WF, Melo RB, Silveira DRA, Velloso E, Rocha V, et al. Assessing early mortality in intensively-treated acute myeloid leukemia in a developing country: Genetic, laboratory findings, and comorbidities add prognostic information. *Blood*. 2020;136:5–6.
132. Hansen BA, Wendelbo Ø, Bruserud Ø, Hemsing AL, Mosevoll KA, Reikvam H. Febrile neutropenia in acute leukemia: Epidemiology, etiology, pathophysiology and treatment. *Mediterranean Journal of Hematology and Infectious Diseases*. 2020;12.
133. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: A

mechanism of immunosuppression in cancer. *Journal of Immunology*. 2001;166:678–89.

134. Biswal S, Godnaik C. Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards. *ecancermedicalscience*. 2013;7:310.
135. Müller L, Di Benedetto S, Pawelec G. The immune system and its dysregulation with aging. *Sub-Cellular Biochemistry*. 2019;91:21–43.
136. Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, et al. Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia. *Hematology (Amsterdam, Netherlands)*. 2012;17:53–8.
137. Halpern AB, Culakova E, Walter RB, Lyman GH. Association of risk factors, mortality, and care costs of adults with acute myeloid leukemia with admission to the intensive care unit. *JAMA Oncology*. 2017;3:374–81.
138. Gao Y, Liu Y, Ma X, Wei L, Chen W, Song L. The incidence and risk factors of peripherally inserted central catheter-related infection among cancer patients. *Therapeutics and Clinical Risk Management*. 2015;11:863–71.
139. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al. Bacteraemia in febrile neutropenic cancer patients. *International Journal of Antimicrobial Agents*. 2007;30.
140. Van der Velden WJFM, Herbers AHE, Netea MG, Blijlevens NMA. Mucosal barrier injury, fever and infection in neutropenic patients with cancer: Introducing the paradigm febrile mucositis. *British Journal of Haematology*. 2014;167:441–52.
141. Garcia JB, Lei X, Wierda W, Cortes JE, Dickey BF, Evans SE, et al. Pneumonia during remission induction chemotherapy in patients with acute leukemia. *Annals of the American Thoracic Society*. 2013;10:432–40.
142. Sangmuang P, Luck Siri A, Katip W. Factors associated with mortality in immunocompetent patients with hospital-acquired pneumonia. *Journal of Global Infectious Diseases*. 2019;11:13–8.

143. Bussini L, Pascale R, Rinaldi M, Bartoletti M. Diagnosis, management and treatment of nosocomial pneumonia in ICU: A narrative review. *Journal of Emergency and Critical Care Medicine*. 2022;6.
144. Cheng GS, Crothers K, Aliberti S, Bergeron A, Boeckh M, Chien JW, et al. Immunocompromised host pneumonia: Definitions and diagnostic criteria: An official American Thoracic Society Workshop Report. *Annals of the American Thoracic Society*. 2023;20:341–53.
145. Vento S, Cainelli F, Temesgen Z. Lung infections after cancer chemotherapy. *The Lancet Oncology*. 2008;9:982–92.
146. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clinical Infectious Diseases*. 2016;63.
147. Evans SE, Safdar A. Pneumonia in the cancer patient. *Principles and Practice of Cancer Infectious Diseases*. 2011.143–52.
148. Wong JL, Evans SE. Bacterial pneumonia in patients with cancer: Novel risk factors and management. *Clinics in Chest Medicine*. 2017;38:263–77.
149. Wanitpongpun C, Teawtrakul N, Lanamtieng T, Chansung K, Siriyeerachai C, Amampai W, et al. Clinical factors predictive of mortality in acute leukemia patients with febrile neutropenia. *American Journal of Blood Research*. 2021;11:59–65.
150. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315:801–10.
151. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. *Intensive Care Medicine*. 2021;47:1181–247.
152. Liu D, Huang SY, Sun JH, Zhang HC, Cai QL, Gao C, et al. Sepsis-induced immunosuppression: Mechanisms, diagnosis and current treatment options. *Military Medical Research*. 2022;9:56.

153. Kraguljac AP, Croucher D, Christian M, Ibrahimova N, Kumar V, Jacob G, et al. Outcomes and predictors of mortality for patients with acute leukemia admitted to the intensive care unit. *Canadian Respiratory Journal*. 2016;2016.
154. Li Y, Ren S, Zhou S. Advances in sepsis research: Insights into signaling pathways, organ failure, and emerging intervention strategies. *Experimental and Molecular Pathology*. 2025;142.
155. Ho G, Wun T, Muffly L, Li Q, Brunson A, Rosenberg AS, et al. Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. *Cancer*. 2018;124:1938–45.
156. Sobas MA, Turki AT, Ramiro AV, Hernández-Sánchez A, EliceGUI JM, González T, et al. Outcomes with intensive treatment for acute myeloid leukemia: An analysis of two decades of data from the HARMONY Alliance. *Haematologica*. 2025;110:1126–40.
157. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. *Journal of Clinical Oncology*. 2018;36:1443–53.
158. Kusuda M, Nakasone H, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, et al. Very early death within 30 days after diagnosis in patients with acute myeloid leukemia. *International Journal of Hematology*. 2023;117:198–205.
159. Van Zant G, Liang Y. Concise review: Hematopoietic stem cell aging, life span, and transplantation. *Stem Cells Translational Medicine*. 2012;1:651–7.
160. Blijlevens NMA, de Mooij CEM. Mucositis and infection in hematology patients. *International Journal of Molecular Sciences*. 2023;24.
161. Gudiol C, Albasanz-Puig A, Laporte-Amargós J, Pallarès N, Mussetti A, Ruiz-Camps I, et al. Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy*. 2020;64.

162. Garcia-Vidal C, Cardozo-Espinola C, Puerta-Alcalde P, Marco F, Tellez A, Agüero D, et al. Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. *PLoS One*. 2018;13.
163. Logan C, Koura D, Taplitz R. Updates in infection risk and management in acute leukemia. *Hematology American Society of Hematology Education Program*. 2020;2020:135–9.
164. Rosa R, Goldani L. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. *Antimicrobial Agents and Chemotherapy*. 2014;58.
165. La Torre G, Mannocci A, Colamesta V, D'Egidio V, Sestili C, Spadea A. Influenza and pneumococcal vaccination in hematological malignancies: A systematic review of efficacy, effectiveness, and safety. *Mediterranean Journal of Hematology and Infectious Diseases*. 2016;8.
166. Hämäläinen S, Kuittinen T, Matinlahti I, Nousiainen T, Koivula I, Jantunen E. Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: Causes and consequences. *Leukemia & Lymphoma*. 2008;49:495–501.
167. Gudiol C, Albasanz-Puig A, Cuervo G, Carratalà J. Understanding and managing sepsis in patients with cancer in the era of antimicrobial resistance. *Frontiers in Medicine*. 2021;8.
168. MacPhail A, Dendle C, Slavin M, Weinkove R, Bailey M, Pilcher D, et al. Sepsis mortality among patients with haematological malignancy admitted to intensive care 2000–2022: A binational cohort study. *Critical Care*. 2024;28:148.

